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1. Introduction 20 
Basal cell carcinoma (BCC) is the most common type of skin cancer among Caucasians constituting 21 
about 75-80% of skin cancer cases [1]. It has a high prevalence in Europe, Australia and the United 22 
States, with approximately 3-4 million cases per year of BCC occur in the United States [2] alone and 23 
the incidence rate is rising by 10% annually worldwide [3]. Common aetiologies for BCC are genetic 24 
predisposition and exposure to solar radiation (UV light). In addition, increasing age, fair skin with 25 
freckles, blond or red hair, blue eyes and male sex represent other risk factors for the condition [4]. 26 
The aims of BCC treatment are complete eradication of the tumour with maximum restoration of 27 
normal function and acceptable cosmetic outcome via surgical or non-surgical intervention [5]. Non-28 
surgical approaches include radiotherapy, photodynamic therapy and topical treatment with 29 
anticancer drugs such as imiquimod (an immune response modifier with antiviral and antitumor 30 
activity) or 5-Fluorouracil (an antimetabolite which inhibits DNA replication in cancer cells). Imiquimod 31 
has been demonstrated to be more effective in the treatment of superficial BCC and can be used as 32 
the first choice treatment [6]. 33 
Surgical excision may not be suitable for some patients because of the invasive nature of the 34 
treatment, poor cosmetic outcome, cost and waiting times [4]. Conversely, topical treatment with an 35 
anticancer drug such as imiquimod provides a non-invasive, self-administered treatment with 36 
excellent cosmetic outcome and lower cost. The four major types of BCC based on morphological 37 
classification are superficial (15%), nodular (50%), infiltrative (20%) and mixed (15%) [7]. Several 38 
clinical studies have demonstrated the efficacy of imiquimod in the treatment of superficial BCC with 39 
cure rates range from 87% to 88% for a 6 week treatment course (once daily/ 5 days per week), while 40 
the cure rates in nodular BCC range from 42% to 76% for a treatment course of 12 weeks (once daily/ 41 
5 days per week) [8]. As such, the drug is yet to be approved by the FDA for the treatment of nodular 42 
BCC. This difference in the clearance rate is attributed to the fact that the lesions in nodular BCC show 43 
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deeper invasion within the dermis with an inability of imiquimod to permeate through the dermal 44 
layer. Several studies have attributed the poor permeation profile of imiquimod within the dermis is  45 
due to its’ low water solubility [9]. In addition, the interaction between the amine groups on the drug 46 
molecule with the anionic components of the skin may contribute to the poor permeation profile of 47 
imiquimod.  48 
Previous studies conducted by Stein et al. [10] and Rehman et al. [11] assessed the permeation of 49 
imiquimod into the skin from Aldara™ cream using HPLC. Stein et al. studied the permeation of 50 
imiquimod from Aldara™ cream across mouse skin and found that 11.5% of imiquimod from Aldara™ 51 
cream permeated across the skin and only 19% remained on the skin surface [10]. Rehman et al. 52 
reported a higher amount of imiquimod permeated from Aldara™ cream than from a bigel 53 
formulation, where the imiquimod content in the tape strips (TS) from Aldara™ cream was found to 54 
be 59.66% of the mean % recovered amount. From both studies  imiquimod displayed a high 55 
permeability profile from Aldara™ cream into the skin, this can be attributed to the use of  mouse skin, 56 
since it is thinner and much more permeable than human or pig skin (up to 10 times) [12]. It is also 57 
worth noting that in both studies, the researchers employed HPLC to quantify the amount of 58 
imiquimod permeated.  However, this analysis does not have any imaging capability and therefore it 59 
cannot identify the spatial distribution of imiquimod within skin. In the treatment of BCC, uniform 60 
distribution is important to ensure complete tumour eradication and hence prevention of future 61 
recurrence.  62 
One of the strategies to assist the delivery of topical therapy to deeper BCC is via the use of 63 
microneedle technology. Microneedles are arrays of micron-size projections with length ranging 64 
between 250-1000 µm providing a minimally invasive means to transport drug molecules into and 65 
across the skin. They are composed of small micron sized needles which pierce the skin to create 66 
microchannels through which drug molecules can be efficiently delivered [13]. In general, 67 
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microneedles can be characterised into five main groups, namely solid, coated, dissolving, hollow and 68 
hydrogel-forming microneedles [14].These devices confer a minimally invasive and pain-free drug 69 
delivery into or across the skin which can improve patient compliance and adherence to treatment. 70 
Unlike hypodermic injections, microneedles don’t cause bleeding or require trained personnel for 71 
administration and can be applied by patients themselves [15].  72 
Microneedles have been used to successfully deliver a range of active pharmaceutical agents (APIs) 73 
ranging from low molecular weight drugs to macromolecules into and across the skin [15]. Donnelly 74 
et al. [16] used a silicon microneedle pre-treatment in vivo to enhance skin penetration of 5-ALA into 75 
mice skin. They found significantly higher levels of the photosensitiser protoporphyrin IX (PpIX) in the 76 
microneedle pre-treated skin compared to intact skin. It is postulated that this microneedle pre-77 
treatment drug delivery approach would be a suitable strategy to improve the delivery of imiquimod 78 
into the skin to treat BCC lesions.  79 
Time-of-flight secondary ion mass spectrometry (ToF-SIMS) is a highly sensitive surface analysis 80 
technique that can be used to characterise the surface chemistry of a sample. ToF-SIMS exhibits high 81 
chemical specificity and provide chemical imaging data [17].  Furthermore, the preparation of samples 82 
for ToF-SIMS analysis is relatively simple and does not require any extraction process that often used 83 
in chromatographic methods or the addition of fluorescent tags or radio-labels [18] except the 84 
removal of the excess moisture from the samples prior the analysis [19]. Judd et al. first used ToF-85 
SIMS to successfully illustrate the permeation of an active agent (chlorhexidine) from 2% w/v aqueous 86 
chlorhexidine solution into porcine skin [18]. Sjövall et al. also utilised ToF-SIMS to image the 87 
distribution of the active pharmaceutical ingredient (API) ‘roflumilast’ in mouse skin [20]. In addition, 88 
Brunelle and co-workers have conducted considerable work on mapping the permeation profile of 89 
fatty acids penetration enhancer  into the skin highlighting the utility of ToF-SIMS tracking the 90 
permeation of exogenous compound into the skin [21–23].  91 
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In this study we used an in vitro Franz cell with subsequent HPLC and ToF-SIMS analysis to illustrate 92 
the permeation depth and lateral distribution characteristics of imiquimod in porcine skin following 93 
the application of AldaraTM cream. The same approach was also used to investigate these aspects 94 
following a skin pre-treatment using a solid stainless-steel microneedling pen in an attempt to improve 95 
the permeation of imiquimod into the skin rendering it more effective in the treatment of deeper 96 
nodular type BCC tumours. 97 
2. Materials 98 
Imiquimod was purchased from Bioscience Life Sciences, UK. Aldara™ 5% cream, MEDA Company, 99 
Sweden was purchased from Manor pharmacy, UK. Dermapen® which is a microneedling pen was 100 
purchased from ZJchao, China. Sodium acetate and isopentane were purchased from Sigma-Aldrich, 101 
UK. Acetonitrile (HPLC grade), glacial acetic acid were obtained from Fisher Scientific, UK. Teepol 102 
solution (Multipurpose detergent) was ordered from Scientific Laboratory Supplies, UK. D-Squame 103 
standard sampling discs (adhesive discs) were ordered from CUDERM corporation, USA. OCT 104 
compound were obtained from VWR International Ltd. Belgium. Deionised water was obtained from 105 
an ELGA reservoir, PURELAB® Ultra, ELGA, UK. All reagents were of analytical grade, unless otherwise 106 
stated. Porcine skin was used to study the permeation profile of imiquimod due to the limited 107 
availability and difficulties associated with the use of ex vivo human skin. Nevertheless, various studies 108 
have highlighted that porcine skin is a suitable alternative due to the similarities in thickness, 109 
histological and permeability properties to human skin [24]. Skin samples were prepared from the 110 
porcine pig ears of six months old obtained from a local abattoir prior any steam cleaning process. The 111 
skin was washed with distilled water and dried using tissue. Hair was carefully cut by scissors to avoid 112 
any damage to the stratum corneum and the subcutaneous fatty layer was removed using a scalpel. 113 
Full skin thickness was used to avoid altering the skin biomechanical properties which may lead to 114 
over-penetration of microneedle into the dermal tissue [25]. After that, the full thickness skin samples 115 
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were wrapped in an aluminium foil and stored at -20 °C. Skin samples were used within six weeks of 116 
being frozen. A skin integrity test was performed by measuring the transepithelial electric resistance 117 
(TEER) using a modified form of EVOM2 Voltohmmeter (World Precision Instruments, USA). Skin 118 
samples passed the skin integrity test if they showed TEER reading ≥  3 KΩ [26]. TEER measurements 119 
were made prior to performing skin permeation experiments. 120 
  121 
3. Methods 122 
3.1. Permeation study of Aldara™ cream through porcine skin 123 
Skin samples were mounted on Franz cells with the stratum corneum facing upwards. The receptor 124 
chamber was filled with 10 mL of 0.1 N HCl used as receptor fluid to keep sink conditions because of 125 
the high solubility of imiquimod (basic compound) in this acidic medium 9.5 mg/mL (tested 126 
experimentally). Franz cells were then placed in a stirring water bath (Cleaver Scientific Ltd., UK) at 37 127 
°C for 30 minutes to equilibrate before applying the formulation. The skin was dosed with 20 mg of 128 
Aldara™ cream on infinite dose basis over an area of 0.64 cm2. Infinite dose experiments are defined 129 
as experiment where the formulation are applied in a manner that ensures continuous excess of test 130 
preparation in the donor compartment. This avoid, the concentration of the drug from being the 131 
limiting factor for the permeation of the formulation. Infinite dose is achieved when 100 µl is applied 132 
per cm2 for liquid formulations or 10 mg per cm2 for solid or semisolid formulation. Such a volume 133 
ensures continuous excess of test preparation in the donor compartment [27]. Such dose will produce 134 
fundamental permeation behavior and is frequently utilised when testing the drug permeation profile 135 
in the presence of permeability enhancers, in this case the permeability enhancement is attributed to 136 
the use of microneedles [28]. .. In order to investigate the utility of microneedles to enhance the 137 
permeation profile of imiquimod from commercially available AldaraTM cream, additional Franz cell 138 
experiments were performed. However, in this experiment prior to assembling the Franz cells, the 139 
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skin was placed on a cork support and the microneedle device was applied vertically on the skin. The 140 
microneedle device contains 12 solid (metal) micro sized needles of 32 gauge (230 µm diameter). The 141 
length of the microneedles used was 250 µm with a minimum speed of vibration of 1000 turn per 142 
minute. The application time was kept to 1 minute with a mild pressure application (thumb pressure).  143 
Thereafter, the skin samples were mounted on Franz cells with the stratum corneum facing upwards 144 
and followed by the application of  the same dose of Aldara™ cream. The receptor fluid for the Franz 145 
cells were stirred continuously by a small Teflon-coated magnetic stir bar at 600 rpm and the 146 
experiment was ran for 24 hours unoccluded.  HPLC analysis for imiquimod content from different 147 
Franz cells’ elements was performed after the 24 hour permeation experiment as detailed in Section 148 
3.4 . 149 
 150 
3.2. Insertion study of microneedles and histological examination of microneedle 151 
treated skin 152 
To demonstrate the penetration efficiency of the microneedle device, an insertion and staining 153 
protocol with en face imaging by a light microscope was followed. Porcine skin was pinned onto a flat 154 
cork board to stretch the skin and the microneedling pen was applied vertically on the skin. An 155 
electronic microneedle device   was used to pierce the skin by vibrational motion of microneedles.. 156 
These application conditions were used throughout all microneedles experiments. Several drops of 157 
gentian violet 1% dye were subsequently applied to cover the treated area and left for 10 minutes. 158 
Afterwards, the excess of the dye was removed from the skin surface by a tissue towel and Azo wipes 159 
(70% v/v IPA, Synergyhealth, UK). The treated skin area was then examined under light microscope 160 
(Leica optical microscope model EC3, Leica Microsystems Ltd., Switzerland) to capture an en face 161 
image for the microneedles treated skin area. 162 
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Following the en face imaging of the skin area treated with microneedles by a light microscope, a 163 
histological examination was carried out to assess the penetration depth achieved by microneedles. 164 
OCT embedding and cryo-sectioning of the skin were performed followed by haematoxylin and eosin 165 
staining. Untreated skin samples with microneedles (blank skin) were also subjected to cryo-166 
sectioning, staining and examination under light microscope. 167 
3.3. Tape stripping of porcine skin post-permeation study  168 
After removing the excess cream from the skin surface, the skin was dismantled from the Franz cells 169 
assembly and left to air dry at ambient temperature for approximately 2 hours. Following this, a tape 170 
stripping technique was employed using adhesive tapes (D-Squame, Standard Sampling Discs, USA) 171 
with a diameter of 22 mm. The adhesive tapes were applied and removed successively from the same 172 
treated skin area for up to 20 strips with the aid of a roller to press the adhesive tape 10 times onto 173 
the skin surface to stretch it to avoid the effects of furrows and wrinkles on the tape stripping 174 
procedure. A constant speed was used to remove the adhesive tapes from the skin surface by tweezers 175 
(in one swift motion) which were then placed in Eppendorf vials and stored at -20 °C until required for 176 
analysis [29].  177 
3.4. Measurement of mass balance and HPLC Analysis 178 
When the Franz cell experiments were completed (after 24 hours), the excess formulation was 179 
removed from the surface of the skin by careful application of a combination of very soft dry and 180 
moistened sponges with 3% v/v Teepol® detergent solution. The sponges were combined and stored 181 
for imiquimod HPLC analysis as a total skin wash. In addition, any cream on the donor chamber inner 182 
surface was also removed by the sponges and stored for imiquimod HPLC as a donor chamber wash. 183 
The amount of imiquimod from the different Franz cell elements (skin wash, donor chamber wash, 184 
pooled tape strips and remaining skin after tape stripping) was extracted by the addition of 20, 10, 5 185 
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and 3 mL of methanol extraction mixture (Methanol 90%: Water 9% : 0.1N HCl 1%) respectively. They 186 
were then vortexed for 2 minutes and left overnight. Following this, they were sonicated for 30 187 
minutes, filtered through 0.45 µm syringe filter and analysed by HPLC. Receptor fluid samples were 188 
filtered through 0.22 µm centrifuge tube filter and injected directly into the HPLC system without any 189 
dilution.  HPLC analysis was carried out using an Agilent 1100 series instrument (Agilent Technologies, 190 
Germany) equipped with degasser, quaternary pump, column thermostat, autosampler and UV 191 
detector. System control and data acquisition were performed using Chemostation software. The 192 
details of the HPLC chromatographic conditions are as follow: column C18 (150 × 4.6 mm) ACE3/ACE-193 
HPLC Hichrom Limited, UK. Mobile phase of buffer: acetonitrile (70:30 v/v), the buffer is of 0.005 M 194 
sodium 1-octanesulfonate in water containing 0.1% triethylamine adjusted with dilute perchloric acid 195 
to pH of 2.2, flow rate of 0.8 mL/minute, UV detection at λ max. 226 nm, injection volume of 10 µL 196 
and column temperature at 25 °C 197 
3.5. Cryotome of porcine skin post-permeation study for ToF-SIMS Analysis 198 
Skin samples removed from Franz cells were placed in a plastic block containing the optimum cutting 199 
temperature (OCT) gel (VWR International Ltd., Belgium) which is an inert mounting medium for 200 
cryotomy that solidifies upon rapid cooling. Therefore, the plastic block containing skin immersed in 201 
OCT was placed in a beaker of isopentane pre-cooled with liquid nitrogen to solidify.  After 202 
solidification, the OCT blocks were wrapped in aluminum foil, placed in an airtight plastic bags and 203 
stored at -80 °C. Cryo-sectioning of skin samples were carried out by placing the OCT block in a cryostat 204 
chamber (Thermo Cryotome™, UK) at a temperature of -20 °C. The block was allowed to equilibrate 205 
within the cryostat chamber for 30 minutes and then sectioned using a steel blade into vertical cross 206 
sections of 20 µm thickness. Following this, the cryo-sections were mounted onto polysine microscope 207 
adhesion slides (ThermoFisher Scientific) and freeze dried for 1 hour prior to ToF-SIMS analysis. 208 
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3.6. ToF-SIMS analysis 209 
 210 
ToF-SIMS was used to analyse individual tape strips and cryo-sectioned skin samples obtained from 211 
Franz cell testing. The tape strips and cryo-sectioned skin samples were placed in a freeze dryer for 1 212 
hour prior to ToF-SIMS analysis. ToF-SIMS analysis was performed using a ToF-SIMS IV instrument 213 
(IONTOF, GmbH) with a Bi3+ cluster source. A primary ion energy of 25 KeV was used, the primary ion 214 
dose was preserved below 1 × 1012 per cm2 to ensure static conditions. Pulsed target current of 215 
approximately 0.3 pA, and post-acceleration energy of 10 keV were employed throughout sample 216 
analysis. The mass resolution for the instrument was 7000 at m/z 28. The area scanned of the tape 217 
strips samples was (9 mm × 9 mm) encompassing the entire skin area exposed to Aldara™ cream during 218 
Franz cell diffusion experiments. For the cryo-sectioned skin samples the scanned area was (6 mm × 6 219 
mm) or (10 mm × 4 mm) depending on the section size. All the samples were analysed at a resolution 220 
of 100 pixels/mm. An ion representing biological material and therefore indicative of skin (skin marker) 221 
was identified as CH4N+ and was used to threshold the data sets.. CH4N+ is a common fragment 222 
observed in organic materials such as biological specimen. Therefore, this secondary ion was used to 223 
track the presence of corneocyte extracted on the tape strips. After that, the data was reconstructed 224 
to remove the data from the adhesive tape material found between the fissures in the stripped skin 225 
(removing the substrate data) and therefore the data was only analysed from the skin material. 226 
Following this, each image of the individual tape strip (9 mm × 9 mm) was divided into four smaller 227 
data sets of (4.5 mm × 4.5 mm) which results in four repeats (n = 4) for each sample and their 228 
intensities were normalised to the total ion intensity. In addition, pure imiquimod and AldaraTM cream 229 
reference spectra were obtained by analysing the pure drug and the cream on silicon wafer using ToF-230 
SIMS. 231 
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4. Results and Discussion 232 
4.1. Measurement of mass balance and HPLC Analysis of Aldara permeation from 233 
porcine skin. 234 
The mean total recovery for mass balance of imiquimod recovered from the different Franz cell 235 
components following the permeation study of Aldara™ cream is graphically illustrated in Figure 1. The 236 
recovery percentage of applied dose is highest in the skin wash (90 %) as compared to other 237 
components indicating that the imiquimod delivered from Aldara™ cream has limited permeation into 238 
the skin. A very minor amount (< 1 %) was recovered from the remaining skin, suggesting that 239 
imiquimod permeation from Aldara™ cream is very limited and is consistent with the FDA approval 240 
details and clinical trials that showed the efficacy of Aldara™ cream just for the treatment of superficial 241 
BCC lesions [30,31].  242 
 243 
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 244 
Figure 1 Mean total recovery for mass balance of applied dose amount of imiquimod from the different Franz cell components 245 
(donor chamber wash, skin wash, tape strips, remaining skin and receptor fluid) of the permeation study of Aldara™ cream 246 
when analysed by HPLC. Data is presented as the mean ± SD (n = 6). The inset provides details on the amount of imiquimod 247 
that have permeated into (tape strips and remaining skin) and across (receptor fluid) the skin. 248 
The amount of imiquimod observed to permeate in this study is less than that observed by Stein et al. 249 
who found 11.5 % in the skin for imiquimod from Aldara™ cream and only 19% remained on the skin 250 
surface when analysed by HPLC [10]. This higher imiquimod permeability observed by Stein et al. can 251 
be attributed to the use of  mouse skin, since it is thinner and much more permeable than human or 252 
pig skin (up to 10 times) [32,33].  253 
The high lipophilicity and low aqueous solubility of imiquimod suggests that it may have easier 254 
permeation into the stratum corneum layer compared with the more aqueous viable epidermis and 255 
therefore it may form a depot within the stratum corneum since the viable epidermis has a high-water 256 
content. Several studies have shown that lipophilic drugs and lipophilic UV filters tend to be preferably 257 
located or accumulated on the skin surface and in the superficial layers of the stratum corneum 258 
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[34,35]. Using porcine skin, as a suitable alternative to human skin, the current results are in 259 
agreement with these findings and highlight the superficial permeation of imiquimod into the skin. 260 
Such finding further corroborate the licensing restriction imposed by the FDA on AldaraTM cream for 261 
the treatment of superficial BCC over the nodular variants. Although the HPLC analysis provide useful 262 
quantitative results, the analytical technique does not confer any detail regarding imiquimod 263 
distribution within individual layers of skin. Therefore, additional analytical techniques were explored 264 
in an attempt to provide such spatial detail regarding imiquimod permeation. 265 
4.2. ToF-SIMS analysis of tape strips post permeation study 266 
Due to the several advantages offered by the ToF-SIMS outlined in Judd et al [18]., this technique was 267 
implemented in this study to glean a more detailed insight into permeation of imiquimod from 268 
Aldara™ cream including an analysis of individual tape strips and imaging of the chemical distribution 269 
of imiquimod at their surface. Prior to ToF-SIMS analysis of the tape stripped, some preliminary ToF-270 
SIMS experiments were performed to obtain reference spectra of pure imiquimod and AldaraTM 271 
cream. ToF-SIMS survey spectra of pure imiquimod and AldaraTM cream reference on silicon wafer in 272 
positive polarity are shown in Figure 2 (a) and (b) respectively. 273 
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 274 
Figure 2 Positive polarity ToF-SIMS survey spectra of (A) imiquimod reference and (b) Aldara™ cream, where the inset spectrum 275 
shows the peak of the [M+H]+ of imiquimod at m/z = 241. (c) Ion intensity values of the [M+H] + of imiquimod in Aldara™ cream 276 
tape strips normalised by total ion intensity. Data is presented as the mean ± SD (n = 4). The dotted black line represents the 277 
ion intensity obtained from the control skin samples. 278 
 279 
 280 
As shown in Figure 2 (a), two secondary ion peaks relevant to imiquimod are observed in the positive 281 
polarity spectra, the molecular ion [M+H]+ peak of imiquimod C14H17N4+ (m/z = 241) and the fragment 282 
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ion peak C10H9N4+ (m/z = 185). The [M+H]+ of imiquimod C14H17N4+ which resulted from the ionisation 283 
of the whole imiquimod molecule C14H16N4 (M.wt. 240) is more intense than the fragment ion peak. 284 
In the negative polarity only a fragment ion peak, C10H8N4─ (m/z = 184), is observed (Supporting 285 
Information, Figure S1). The positive polarity data is therefore considered to be more informative than 286 
the negative polarity due to the presence of the [M+H] + at a relatively high intensity which provides 287 
unambiguous identification of imiquimod. Therefore, the ToF-SIMS data of imiquimod will be 288 
presented in the positive mode only. 289 
The ToF-SIMS survey spectrum of Aldara™ cream is shown in Figure 2 (b). Although the peak of the 290 
[M+H]+ of imiquimod in Aldara™ cream is not as intense as observed for the pure imiquimod reference 291 
material Figure 2 (a), it is clearly resolved suggesting that ToF-SIMS can be used to identify imiquimod 292 
in Aldara™ cream. 293 
To assess the exact permeation of imiquimod and visualise its distribution within the stratum 294 
corneum, tape strips obtained from Franz cell experiments were analysed by ToF-SIMS. The secondary 295 
ion intensity data for the [M+H]+ ion of imiquimod in Aldara™ cream treated skin tape strips are shown 296 
in Figure 2 (c) whereby it can be observed that this ion is observed above the control intensity 297 
throughout the series of 18 tape strips (therefore approximately illustrating the full depth of the 298 
stratum corneum). A decreasing ion intensity is observed from the outer surface of the skin (TS 1) to 299 
the inner layers of the stratum corneum (TS 18). The ability of the ToF-SIMS to analyse single tape 300 
stripped skin samples (layer by layer of skin analysis) to map the permeation of imiquimod within the 301 
stratum corneum has not been previously observed and this study provides further insight into the 302 
exact depth of permeation achieved with this drug. This decreasing permeation of imiquimod at the 303 
inner layers of the stratum corneum is consistent with the HPLC results that demonstrated a limited 304 
permeation of imiquimod into the deeper skin layers (less than 1% recovered from the remaining skin 305 
specimen).  306 
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ToF-SIMS ion images of the entire tape stripped area, which represents the whole exposed area of the 307 
skin to Aldara™ cream during Franz cell diffusion experiment (9 mm diameter), are illustrated in  308 
Figure 3. The total,  skin marker (CH4N+), and imiquimod marker (C14H17N4+) ion images are shown in 309 
Figure 3 (a, b and c respectively. The intensity are scaled to the same value to enable a valid or fair 310 
comparison.  311 
 312 
Figure 3 ToF-SIMS ion images of Aldara™ cream treated skin tape strips showing the (a) the total (b) skin marker (CH4N+) and 313 
(c) imiquimod marker (C14H17N4+) ions. The scanned area is (9 mm × 9 mm). 314 
An examination of the skin marker, CH4N+ (Figure 3 (b), shows that the amount of skin (corneocytes) 315 
attached per tape strip is reduced moving from the outer skin surface (TS 1) towards the inner layers 316 
of the stratum corneum (TS 18).  Although there is some reduction, the significant reduction appears 317 
to occur at around TS 12 and that TS 1, 2 and 6 show a large amount of stripped corneocytes. This 318 
would be anticipated and similar observations of decreasing skin amount from the upper to lower 319 
tape strips have been reported by other studies when corneocytes on tape strips were determined by 320 
different methods such as the weighing method, protein assay method and UV/visible method. This 321 
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is due to the increased cohesion between the cells at the deeper stratum corneum layers compared 322 
to the outer layers which results in reduced amounts of skin being removed by a tape strip [36–38].  323 
The ion images of the [M+H]+ of imiquimod (Figure 3c) are observed to decrease from the uppermost 324 
layer (TS 1) towards the deeper layer of the stratum corneum (TS 18) correlating with the ion intensity 325 
data shown in Figure 2 (c). Although TS 1 and 2 show a non-uniform distribution of the M+H+ ion, there 326 
are very few instances where the M+H+ ion is not present coincident with the skin marker. This 327 
suggests that within the first two layers of skin the imiquimod has permeated significantly and would 328 
potentially explain its ability to successfully treat superficial BCC tumours. The skin marker for TS 6 329 
shows some reduction in the amount of skin removed but nonetheless still shows most of the Franz 330 
cell area. The ion distributions within TS 6 exhibit some areas where the M+H+ for imiquimod and the 331 
skin marker do not correlate, where the M+H+ for imiquimod is absent. It is proposed that although 332 
imiquimod has permeated to this layer of the skin, it has not done so uniformly with absent patches 333 
up to several millimetres in diameter. It is evident from the skin marker ion that TS 12 and 18 exhibits 334 
significantly less skin than previous strips, however, it is clear that relatively little of the M+H+ ion of 335 
imiquimod can be observed correlating with the location of the skin. It is proposed that some 336 
imiquimod has permeated to the lower region of the stratum corneum, however, it has done so in 337 
very small areas often no larger than 1 mm in diameter.    338 
This observed non-uniform distribution of imiquimod within skin from TS 6 onwards can decrease the 339 
efficacy of Aldara™ cream to effectively treat whole BCC lesions. The pattern of drug distribution within 340 
the skin layers is very important in BCC because the whole lesion area should be treated evenly at the 341 
effective concentration to ensure complete cure and prevent recurrence. Therefore, the ability to 342 
assess this is of great importance, since the topical treatment of BCC lesions with Aldara™ cream has 343 
shown higher recurrence rate in comparison to surgery [8], particularly tumours with thickness > 0.4 344 
mm [39].  These findings show detailed permeation of imiquimod down to TS 18. The non-uniformity 345 
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in later layers supports the rationale of why FDA restrict the license of AldaraTM for the treatment of 346 
superficial BCC over nodular BCC. 347 
4.3. Insertion study of microneedles and histological examination of microneedle 348 
treated skin 349 
Given the limited permeation profile of imiquimod when applied as a topical cream, the utility of a 350 
skin pre-treatment using a microneedle pen as a permeation enhancement strategy was pursued. 351 
However, prior to this, the insertion profile of the device was investigated. The image of the 12-metal 352 
microneedle cartridge that is fixed in the microneedle device is shown in Figure 4 (a). The diameter of 353 
the base (circular shape) containing the 12 microneedles is 5 mm and the distance between each 354 
microneedle pin is approximately 1.5 mm.  355 
To demonstrate the efficiency of the microneedle device to penetrate the uppermost layer of the skin, 356 
en face imaging by light microscopy was performed for the porcine skin samples treated with the 357 
microneedles and stained with gentian violet as illustrated in Figure 4 (b). These images show that the 358 
dyes are appropriately retained in the microchannels formed by the microneedles. This indicates the 359 
capability of the microneedles to successfully pierce the skin.  360 
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 361 
Figure 4 En face images of (a) the microneedles cartridge fixed in the microneedle device used to pierce the skin, (b) porcine 362 
skin following microneedle device treatment and staining with gentian violet. (c) Light microscope images H&E stained cross-363 
sections identifying the location of the microchannels within skin tissue (d) H&E stained cross-sections but at a higher 364 
magnification. 365 
 366 
The microneedling pen penetration efficiency was observed to occur in a reproducible manner 367 
throughout the tested skin samples which can be attributed to the fixed velocity used in the 368 
microneedles insertion provided by the microneedle device. Verbaan et al. demonstrated that the use 369 
of an electrical applicator for microneedles with 300 µm length at certain velocity facilitates the 370 
insertion of the microneedles into the skin in a reproducible manner compared to manual application 371 
[40]. The stained cross-sections with H&E highlight the location of the microchannels within skin tissue 372 
and it can be observed that the microneedles penetrate the stratum corneum and viable epidermis to 373 
reach the papillary dermis (PD) layer (the layer located directly beneath the viable epidermis). In order 374 
to measure the pore size, the diameter of the stained pores could be measured to provide an estimate 375 
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of the size of the microchannels formed. However, as diffusion may occur, a more accurate way to 376 
estimate the pores diameter is to cryo-section the skin samples directly following insertion and 377 
measure the channel diameter via microscopy. It can be seen from Figure 4 b that the measured 378 
diameter of the pores ranged from 300 to 500 µm. However, these values are in contrast to the 379 
measured values from the cryo-sectioned samples (Figure 4 c and d) that showed the diameter of the 380 
pores to be between 40 and 95 µm. This overestimation of the pore size is thought to be due to the 381 
lateral diffusion of the dyes to the surrounding dermal tissue. An apparent limitation of the en face 382 
imaging method of visualising microneedles treated skin is the overestimation of the pore diameter 383 
because of the lateral diffusion of the dyes [41,42]. In addition, a recent study conducted by Coulman 384 
et al. highlighted that such overestimation may also arise from tissue processing steps which influence 385 
tissue hydration and elasticity of the skin [42]. However, such overestimation will not affect the goal 386 
of the study which is to use the microneedling pen to breach the stratum corneum in order to generate 387 
conduits to promote the delivery of imiquimod into the skin. A noteworthy point is that the 388 
microneedle cartridge fixed to microneedle device is disposable and can be used just for one 389 
application and then replaced with a new one for the next sample. This diminishes any damage that 390 
may occur to the integrity of microneedles from repeated applications and increases the microneedles 391 
penetration reproducibility. Simultaneously, from the clinical perspective this eliminates any safety 392 
issue generated from the breaking of the microneedles within skin from the reuse of the same 393 
microneedles. 394 
.  395 
22 
 
4.4. Mass balance measurement and HPLC Analysis of Imiquimod from AldaraTM 396 
application on microneedle pre-treated skin. 397 
The mean percentage recovered amounts of imiquimod from the different Franz cell elements of the 398 
permeation study of Aldara™ cream with and without microneedles pre-treatment are reported in  399 
Table 1. It is observed in Table 1 that the mean percentage recovered amount of imiquimod from tape 400 
strips and remaining skin elements of Aldara™ cream with microneedles pre-treatment is 401 
approximately three times higher than the Aldara™ cream alone. This provides a greater opportunity 402 
for the cream to more efficiently treat whole superficial or nodular BCC lesions. In addition, the 403 
statistical comparison between the recovered amounts of imiquimod in the remaining skin shows that 404 
the recovered amount of imiquimod with microneedle pre-treatment is significantly higher (Unpaired 405 
Student’s t-test p<0.05) than the Aldara™ cream alone as illustrated in Figure 5.  406 
 407 
 408 
 409 
Table 1 Mean percentage recovered amount of imiquimod from the different Franz cell elements of the permeation study of 410 
Aldara™ cream with and without microneedle pre-treatment when analysed by HPLC. Data is presented as the mean % ± SD 411 
(n = 6) 412 
Analysed 
Element Aldara
™ cream only                         
(mean % recovery ± SD) 
Aldara™ cream with microneedles           
pre-treatment                                      
(mean % recovery ± SD) 
Donor wash 7.11 ± 3.27 9.38 ± 4.59 
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Skin wash 81.72 ± 8.14 72.39 ± 12.02 
Tape strips 0.67 ± 0.13 2.38 ± 2.40 
Remaining skin 0.81 ± 0.26 2.27 ± 0.39 
Receptor fluid 0.17 ± 0.08 1.89 ± 0.47 
 413 
 414 
 415 
Figure 5 Mean percentage recovered imiquimod amount in the remaining skin of the permeation study of Aldara™ cream 416 
with and without microneedle pre-treatment when analysed by HPLC. Data is presented as the mean ± SD (n = 6). Unpaired 417 
Student’s t-test p<0.05 418 
 419 
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Furthermore, it is observed that with microneedle pre-treatment the imiquimod’s amount in the 420 
receptor fluid is approximately ten times higher than the Aldara™ cream alone. This increase in the 421 
recovered amount of imiquimod in the receptor fluid is perhaps anticipated since the microchannels 422 
created by microneedles can reach the depth of the papillary dermis layer and thus higher amounts 423 
of imiquimod bypass the skin barriers and are presented in the receptor fluid. For in vivo conditions, 424 
this would suggest that higher amounts of imiquimod would be available for systemic circulation 425 
which may lead to increase the risk of imiquimod’s systemic adverse effects. However, in BCC patients 426 
the stratum corneum becomes thicker because of the hyperkeratinisation associated with the tumour 427 
lesions [30] and the microchannels created by microneedle device may not reach the depth of 428 
papillary dermis and hence less amounts of imiquimod would be available for systemic absorption. 429 
Besides that, it could be argued that the utilisation of such device may push cancerous cells from 430 
superficial BCC into the dermis leading to the potential risk of seeding and spreading the cancer cell 431 
in a new dermal microenvironment. However, the propensity for such phenomenon is minimal due to 432 
the nature of BCC cells which is highly dependent on its microenvironment for survival[43]. However, 433 
in an attempt to limit the likelihood of such side effect, the use microneedle device could be reserved 434 
only for deeper BCC lesions such as those seen in nodular and infiltrative BCC. 435 
4.5. ToF-SIMS Analysis of Tape Strips from skin pre-treated with microneedles and 436 
subsequent AldaraTM cream application 437 
ToF-SIMS analysis of the tape strips of Aldara™ cream on microneedle pre-treated skin shows a 438 
significant increase in the ion intensity of the [M+H]+ of imiquimod in tape strips 2, 5 and 10 h for the 439 
microneedles pre-treatment samples as shown in Figure 6  (a). This indicates that a higher amount of 440 
imiquimod had permeated into the stratum corneum following microneedles application which is in 441 
accordance with the HPLC results (Table 1). 442 
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 443 
Figure 6 a) Ion intensity values of the [M+H] + of imiquimod (C14H17N4+) in Aldara™ cream tape strips (2, 5 and 10) with and 444 
without microneedles pre-treatment normalised by total ion intensity. Data is presented at the mean ± SD (n = 4). Unpaired 445 
Student’s t-test p<0.05 (b) ToF-SIMS ion images of tape strip two of Aldara™ cream with microneedles pre-treatment showing: 446 
the skin marker (CH4N+), the imiquimod marker (C14H17N4+), and the overlaid image of imiquimod (green colour) and the skin 447 
(red colour). The scanned tape strip area is of 12 × 12 mm2. 448 
ToF-SIMS ion images of tape strip two of Aldara™ cream with microneedles pre-treatment are shown 449 
in Figure 6 (b). It can be seen that the pattern of imiquimod distribution follows the pattern of the 450 
microneedle array on the derma pen (Figure 4 (a)). In addition, imiquimod is mostly localised in the 451 
area disrupted by the application of the microneedle device (i.e. at a circular region in the middle of 452 
the tape strip which corresponds to the shape of the microneedle device cartridge). Figure 6 (b) also 453 
shows that imiquimod ion, highlighted in green, laterally diffuses out of the microchannels and 454 
distributes to the peripheral epidermal tissue. Such findings indicate that the utilisation of 455 
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microneedling pen in tandem with AldaraTM cream application is able to promote lateral permeation 456 
of drug to surrounding skin tissues. Such apparent lateral permeations have been observed by various 457 
groups using conventional techniques such as fluorescent microscopy. These groups have attributed 458 
that the observed lateral permeation is due to the overlapping drug diffusion fronts from individual 459 
microneedle sites [44,45]. However, it there is yet any research to date that have observed 460 
enhancement in lateral permeation using ToF-SIMS. 461 
. 462 
4.6. ToF-SIMS Analysis of Skin Cross-sections 463 
ToF-SIMS analysis of cryo-sectioned skin samples were used to map imiquimod permeation within 464 
different skin layers. Skin cross-sectioning can be used as a complementary tool to the tape stripping 465 
technique to follow and visualise drug permeation within skin. ToF-SIMS analysis of the cryo-sectioned 466 
skin samples shows that the ion intensity of the [M+H]+ imiquimod from Aldara™ cream with 467 
microneedle pre-treatment is significantly higher than the ion intensity obtained from the samples 468 
without microneedles pre-treatment as shown from their overlaid spectra (Supporting Information 469 
Figure S2). This corresponds with the data obtained by tape stripping shown in Figure 6 (a). It is 470 
thought with the presence of the microchannel created by microneedles application, imiquimod 471 
penetration is not only restricted to the microchannel site but it radiates to the adjacent tissue (lateral 472 
distribution as observed in Figure 6 (b)) which results in almost continuous higher intensity zones of 473 
imiquimod localised at the upper skin strata.  474 
The whole ToF-SIMS ion images of the cryo-sectioned skin samples of Aldara™ cream with 475 
microneedles pre-treatment are illustrated in Figure 7 which show the total and the overlay image of 476 
the skin marker, CH4N+ with imiquimod molecular ion C14H17N4+ (Figure 7 a and b respectively) . An 477 
examination of the total ion image and the skin marker image indicates the location of the 478 
microchannels within the skin sections (white arrows in Figure 7 (a and b)) created by the application 479 
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of microneedles. The [M+H] + imiquimod ion image shown in the overlay image (Figure 7 (b)) highlights 480 
the distribution of imiquimod at the upper layer of the skin sections in addition to its localisation in 481 
the microchannels. It is apparent from that there are some indentations in the skin that may have 482 
formed upon microneedle application. However, not the entire top layer of the cross-section contains 483 
such indentations despite the entire section of the skin analysed covers the entire microneedle treated 484 
region. This may be due to the viscoelastic nature of the skin that causes some region of the skin to 485 
recoil and recover over time from the indentations formed from microneedle application.   486 
For evaluating the difference between the two treatments in Figure 7 (b), it is worth highlighting that 487 
the imiquimod signal arising from the SC is of great interest for the comparison. From the figure it is 488 
evident that there is limited availability of imiquimod within the skin layers when applied as a topical 489 
cream alone. However, when AldaraTM is applied to the microneedle pre-treated skin, we can observe 490 
that imiquimod is mostly located in the stratum corneum which makes imiquimod available in this 491 
layer. Such observation would suggest lateral permeation of imiquimod following cream application 492 
on microneedle treated skin which further supports Figure 6. It is clear here that the imaging capability 493 
of ToF-SIMS illustrates where the drug is localised within the skin tissues. Such findings may be of 494 
heuristic value in guiding the development of such systems in order to improve intradermal delivery 495 
of therapeutics. However, we are unable to see imiquimod in deeper layer using cross-sections as the 496 
drug is diluted over a wide area of the dermis and epidermis. In comparison, the HPLC data from Table 497 
1 suggest increased intradermal delivery with microneedle skin pre-treatment. Such imiquimod 498 
detection was achieved as the extraction procedure concentrates imiquimod from the remaining skin 499 
allowing detection with the HPLC instrument.  500 
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 501 
 502 
 503 
 504 
Figure 7 ToF-SIMS ion distribution map of porcine skin cross sections from Aldara™ cream on intact skin and microneedles 505 
pre-treated skin. (a) the total ion+, (b) an overlay image of the skin marker (CH4N+) with imiquimod marker (C14H17N4+) to 506 
indicate the localisation of imiquimod within the stratum corneum. SC indicates stratum corneum, D indicates dermis. White 507 
arrows indicate microneedle indentation into the skin that still persist after 24 hours. The skin cross-section covers the 508 
microneedle-treated part of the skin as the microneedle array is 5mm wide. 509 
The HPLC and ToF-SIMS results of Aldara™ cream with microneedles pre-treatment quantitatively and 510 
qualitatively demonstrate increased delivery of imiquimod into the epidermal skin layers and suggest 511 
its potential usefulness for more efficient treatment of both superficial and nodular BCC lesions. In 512 
addition, both the Aldara™ cream and the microneedle device are commercially available systems 513 
making them easily accessible. This study is considered to be a proof-of-concept analysis providing an 514 
insight into the potential use of microneedles for improving imiquimod’s skin penetration and further 515 
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ex vivo and in vivo investigation on human skin with BCC lesions are required to optimise the final 516 
application conditions.  517 
5. Conclusion 518 
The current work demonstrates a novel application of Franz diffusion cells, skin tape stripping and skin 519 
cryo-sectioning with subsequent analysis by HPLC and ToF-SIMS to map and visualise the distribution 520 
of imiquimod into the skin from the commercial product Aldara™. The ToF-SIMS ion images of Aldara™ 521 
cream tape strips illustrated a non-uniform distribution of imiquimod within deeper skin strata which 522 
is consistent with the FDA approval and clinical trials for the treatment of superficial BCC. In addition, 523 
this study also highlights the potential advantages of solid microneedles skin pre-treatment in 524 
conjugation with Aldara™ cream application to enhance delivery of imiquimod into the epidermal 525 
layers of the skin for the treatment of the deeper and more invasive nodular BCC lesions. This work 526 
also demonstrates the heuristic value and complementary role of ToF-SIMS technique in the analysis 527 
and imaging of imiquimod permeation into the skin with high sensitivity and chemical specificity 528 
without the need of fluorescent tags or radiolabels. 529 
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